Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Tue, 12.11.2024
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter
€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected c [ … ]
Thu, 07.11.2024
CureVac
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, Germany/BOSTON, USA – November 7, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will r [ … ]
Mon, 04.11.2024
CureVac
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Experienced CFO and investment banker with 30-year track record will help drive CureVac’s transformation
TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmac [ … ]
Mon, 04.11.2024
CureVac
CureVac to Present at the 12th International mRNA Health Conference
TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that new and updated data will be share [ … ]
Mon, 28.10.2024
CureVac
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, Germany/BOSTON, USA – October 28, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced poster presentati [ … ]
Fri, 13.09.2024
CureVac
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy
84% of immune responses were de novo, observed in pa [ … ]
Fri, 13.09.2024
CureVac
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy
84% of immune responses were de novo, observed in pa [ … ]
Thu, 12.09.2024
CureVac
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints
Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone
GSK [ … ]
Thu, 12.09.2024
CureVac
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints
Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone
GSK [ … ]
Mon, 09.09.2024
CureVac
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the f [ … ]